Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
Tag: Merck & Company Inc
Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?
Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
Asia-Pacific Countries Rush to Buy Merck Covid Pill
The home treatment, molnupiravir, is said by the company to potentially halve the risk of hospitalization and death from the virus.
Ivermectin Won’t Treat Covid-19, but Demand Is High Anyway
Clinical trials have repeatedly failed to show that the drug is effective against the virus. Still, U.S. demand is high.
Drug Giants Create Fund to Bolster Struggling Antibiotic Start-Ups
New medicines are desperately needed to treat a growing number of drug-resistant infections, but many companies developing the drugs are short on cash and investments.
Someday, an Arm Implant May Prevent H.I.V. Infection for a Year
In preliminary tests, a matchstick-size rod containing a new drug offered promise as a shield against the virus. But a large clinical trial must still be done.
Global Health: A New Ebola Vaccine Strategy in Africa: Smaller Doses
As violence makes it harder to reach stricken villages in Congo, experts plan to stretch supplies and to give the vaccine to everyone, not just contacts of victims.